Cargando…
The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan Africa. The seroprevalence for KSHV is high in the region, and no prophylactic vaccine against the virus is available. In...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150787/ https://www.ncbi.nlm.nih.gov/pubmed/32111001 http://dx.doi.org/10.3390/v12030256 |
_version_ | 1783521098177970176 |
---|---|
author | Mortazavi, Yasaman Lidenge, Salum J. Tran, Tara West, John T. Wood, Charles Tso, For Yue |
author_facet | Mortazavi, Yasaman Lidenge, Salum J. Tran, Tara West, John T. Wood, Charles Tso, For Yue |
author_sort | Mortazavi, Yasaman |
collection | PubMed |
description | Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan Africa. The seroprevalence for KSHV is high in the region, and no prophylactic vaccine against the virus is available. In this study, we characterized the antigenic targets of KSHV-specific neutralizing antibodies (nAbs) in asymptomatic KSHV-infected individuals and KS patients with high nAbs titers. We quantified the extent to which various KSHV envelope glycoproteins (gB, ORF28, ORF68, gH, gL, gM, gN and gpK8.1) adsorbed/removed KSHV-specific nAbs from the plasma of infected individuals. Our study revealed that plasma from a majority of KSHV neutralizers recognizes multiple viral glycoproteins. Moreover, the breadth of nAbs responses against these viral glycoproteins varies among endemic KS, epidemic KS and asymptomatic KSHV-infected individuals. Importantly, among the KSHV glycoproteins, the gH/gL complex, but neither gH nor gL alone, showed the highest adsorption of KSHV-specific nAbs. This activity was detected in 80% of the KSHV-infected individuals regardless of their KS status. The findings suggest that the gH/gL complex is the predominant antigenic determinant of KSHV-specific nAbs. Therefore, gH/gL is a potential target for development of KSHV prophylactic vaccines. |
format | Online Article Text |
id | pubmed-7150787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71507872020-04-20 The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals Mortazavi, Yasaman Lidenge, Salum J. Tran, Tara West, John T. Wood, Charles Tso, For Yue Viruses Article Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan Africa. The seroprevalence for KSHV is high in the region, and no prophylactic vaccine against the virus is available. In this study, we characterized the antigenic targets of KSHV-specific neutralizing antibodies (nAbs) in asymptomatic KSHV-infected individuals and KS patients with high nAbs titers. We quantified the extent to which various KSHV envelope glycoproteins (gB, ORF28, ORF68, gH, gL, gM, gN and gpK8.1) adsorbed/removed KSHV-specific nAbs from the plasma of infected individuals. Our study revealed that plasma from a majority of KSHV neutralizers recognizes multiple viral glycoproteins. Moreover, the breadth of nAbs responses against these viral glycoproteins varies among endemic KS, epidemic KS and asymptomatic KSHV-infected individuals. Importantly, among the KSHV glycoproteins, the gH/gL complex, but neither gH nor gL alone, showed the highest adsorption of KSHV-specific nAbs. This activity was detected in 80% of the KSHV-infected individuals regardless of their KS status. The findings suggest that the gH/gL complex is the predominant antigenic determinant of KSHV-specific nAbs. Therefore, gH/gL is a potential target for development of KSHV prophylactic vaccines. MDPI 2020-02-26 /pmc/articles/PMC7150787/ /pubmed/32111001 http://dx.doi.org/10.3390/v12030256 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mortazavi, Yasaman Lidenge, Salum J. Tran, Tara West, John T. Wood, Charles Tso, For Yue The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals |
title | The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals |
title_full | The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals |
title_fullStr | The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals |
title_full_unstemmed | The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals |
title_short | The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals |
title_sort | kaposi’s sarcoma-associated herpesvirus (kshv) gh/gl complex is the predominant neutralizing antigenic determinant in kshv-infected individuals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150787/ https://www.ncbi.nlm.nih.gov/pubmed/32111001 http://dx.doi.org/10.3390/v12030256 |
work_keys_str_mv | AT mortazaviyasaman thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT lidengesalumj thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT trantara thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT westjohnt thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT woodcharles thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT tsoforyue thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT mortazaviyasaman kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT lidengesalumj kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT trantara kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT westjohnt kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT woodcharles kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals AT tsoforyue kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals |